Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3946

Sort by

Sort Order Select

Journal Articles

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Reyka G. Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie Ritchey, Jaebok Choi, Camille N. Abboud, Iskra Pusic, Meagan Jacoby, Peter Westervelt, Matthew Christopher, Amanda Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L. Uy, John F. DiPersio

Blood (2025) 145 (13): 1382–1394.

https://doi.org/10.1182/blood.2024026497

Published: 2025

Includes: Supplemental data

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Journal Articles

Sickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review

Lachelle D. Weeks, Allecia M. Wilson, Rakhi P. Naik, Yvonne Efebera, M. Hassan Murad, Anjlee Mahajan, Patrick T. McGann, Madeleine Verhovsek, Angela C. Weyand, Ahmar U. Zaidi, Michael R. DeBaun, Chancellor Donald, Roger A. Mitchell

Blood (2025) 145 (13): 1345–1352.

https://doi.org/10.1182/blood.2024026899

Published: 2025

Includes: Supplemental data

Journal Articles

Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results

Blood blood.2024027620.

https://doi.org/10.1182/blood.2024027620

Published: 2025

Includes: Supplemental data

Journal Articles

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Blood (2025) 145 (12): 1282–1292.

https://doi.org/10.1182/blood.2024026685

Published: 2025

Includes: Supplemental data

Journal Articles

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Zachariah DeFilipp, Haesook T Kim, Laura W. Knight, Suzanne M. O'Connor, Shilton E. Dhaver, Meghan White, Bhagirathbhai Dholaria, Mark A Schroeder, Sumithira Vasu, Sameem M Abedin, Jooho Chung, Areej El-Jawahri, Matthew J. Frigault, Steven L. McAfee, Richard A. Newcomb, Paul V O'Donnell, Thomas R. Spitzer, Yi-Bin Chen, Gabriela S Hobbs

Blood blood.2024028005.

https://doi.org/10.1182/blood.2024028005

Published: 2025

Includes: Supplemental data

Journal Articles

Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study

Matthew J. Frigault, Richard T. Maziarz, Jae H Park, Aleksandr Lazaryan, Nirav N Shah, Jakub Svoboda, Lazaros J. Lekakis, Ran Reshef, Christine L. Phillips, Lea Burke, Jing Lei, Michael Pratta, Rodica Morariu-Zamfir, John F. DiPersio

Blood blood.2024026586.

https://doi.org/10.1182/blood.2024026586

Published: 2025

Includes: Supplemental data

Journal Articles

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

De Zhou, Xianbo Huang, Lixia Zhu, Xuelian Hu, Xiudi Yang, Mixue Xie, Xin Huang, Fang Yu, Juying Wei, Liya Ma, Jingjing Zhu, Shuqi Zhao, Wanzhuo Xie, Hongyan Tong, Jie Jin, Xiujin Ye

Blood blood.2024026139.

https://doi.org/10.1182/blood.2024026139

Published: 2025

Includes: Supplemental data

Journal Articles

Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Monica S. Nair, Sara K. Silbert, Kai Rejeski, Karilynn A. Wilson, Adam J. Lamble, Yannis Valtis, Bonnie Yates, Alexa Morales Arana, Roni Shouval, Kevin Curran, Rebecca A. Gardner, Haneen Shalabi, Colleen Annesley, Jae H. Park, Marion Subklewe, Nirali N. Shah

Blood (2025) 145 (11): 1136–1148.

https://doi.org/10.1182/blood.2024025910

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes

Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, Shaun Fleming, Chun Yew Fong, Uma Borate, Meagan A. Jacoby, Daniel Nowak, Maria R. Baer, Pierre Peterlin, Brenda Chyla, Huipei Wang, Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia-Manero

Blood (2025) 145 (11): 1126–1135.

https://doi.org/10.1182/blood.2024025464

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma

Blood blood.2024027109.

https://doi.org/10.1182/blood.2024027109

Published: 2025

Includes: Supplemental data

Journal Articles

A Controlled Trial for Preventing Priapism in Sickle Cell Anemia: Hydroxyurea plus Placebo vs Hydroxyurea plus Tadalafil

Ibrahim Musa Idris, Aminu Abba Yusuf, Ismail Isah Ismail, Awwal Musa Borodo, Mustapha Shuaibu Hikima, Shehu Abubakar Kana, Tukur Aliyu, Kabiru Musan Gedu, Atiku Usman Jibrillah, MBBS, FWACS, Sani Ali Aji, Aisha Kuliya-Gwarzo, Kabeer Bello Mohammed, Jamil A . Galadanci, Rukayya Sunusi Alkassim, Mohammad Abba Suwaid, Nafiu Hussaini, Mark Rodeghier, Arthur Louis Burnett, II, Michael R DeBaun

Blood blood.2024027898.

https://doi.org/10.1182/blood.2024027898

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Guy Young, Kaan Kavakli, Robert Klamroth, Tadashi Matsushita, Flora Peyvandi, Steven W. Pipe, M.D., Savita Rangarajan, Ming-Ching Shen, Alok Srivastava, Jing Sun, Huyen A Tran, Chur-Woo You, Bulent Bülent Zülfikar, Laurel A. Menapace, Chuanwu Zhang, Yuqian Shen, Marja Puurunen, Marek Demissie, Gili Kenet

Blood blood.2024027008.

https://doi.org/10.1182/blood.2024027008

Published: 2025

Includes: Supplemental data

Journal Articles

Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAF V600E loads

Blood (2025) 145 (10): 1061–1073.

https://doi.org/10.1182/blood.2024025625

Published: 2025

Includes: Supplemental data

Journal Articles

Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia

Peihua Lu, Xian Zhang, Junfang Yang, Jingjing Li, Liyuan Qiu, Meiwei Gong, Hui Wang, Jiaqi Chen, Hongxing Liu, Min Xiong, Ying Liu, Lin Wang

Blood (2025) 145 (10): 1022–1033.

https://doi.org/10.1182/blood.2024024861

Published: 2025

Includes: Supplemental data

Journal Articles

Air pollution is associated with increased risk of venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis

Pamela L. Lutsey, Jeffrey R. Misialek, Michael T. Young, Jesse Berman, Claire L. Leiser, Zachary C. Pope, Mary Cushman, Aaron R. Folsom, Joel D. Kaufman

Blood (2025) 145 (10): 1089–1096.

https://doi.org/10.1182/blood.2024026399

Published: 2025

Includes: Supplemental data

Journal Articles

End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?

Mengyang Di, Matthew J. Maurer, Christopher R. Flowers

Blood blood.2024026978.

https://doi.org/10.1182/blood.2024026978

Published: 2025

Journal Articles

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Dan T. Vogl, Shebli Atrash, Sarah A. Holstein, Omar Nadeem, Don Benson, Maria Chaudry, Noa Biran, Kaveri Suryanarayan, Cheryl Li, Yuyin Liu, Sabrina Collins, Xavier Parot, Jonathan L. Kaufman

Blood (2025) 145 (9): 944–955.

https://doi.org/10.1182/blood.2024026124

Published: 2025

Includes: Supplemental data

Journal Articles

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

Blood (2025) 145 (9): 970–974.

https://doi.org/10.1182/blood.2024025624

Published: 2025

Includes: Supplemental data

Journal Articles

Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17

Adalgisa Condoluci, Ilaria Romano, Daniel Dietrich, Katia Pini, Georg Stussi, Gisela Müller, Nathan Cantoni, Richard Cathomas, Ulrich J.M. Mey, Anouk Andrea Widmer, Thorsten Zenz, Michael Gregor, Dominik Heim, Martin Andres, Rudolf Benz, Davide Rossi

Blood blood.2024026879.

https://doi.org/10.1182/blood.2024026879

Published: 2025

Includes: Supplemental data

NARROW

Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Sickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review

Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results

MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

Itacitinib for the Prevention of IEC Therapy-Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China

Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia

Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes

Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma

A Controlled Trial for Preventing Priapism in Sickle Cell Anemia: Hydroxyurea plus Placebo vs Hydroxyurea plus Tadalafil

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAF V600E loads

Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia

Air pollution is associated with increased risk of venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis

End points and Outcomes in Follicular Lymphoma: What should we measure, how, and why?

Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma

Approaching hypercalcemia in monoclonal gammopathy of undetermined significance: insights from the iStopMM screening study

Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only